Hans‐Peter Sinn

20.1k total citations · 1 hit paper
260 papers, 8.3k citations indexed

About

Hans‐Peter Sinn is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, Hans‐Peter Sinn has authored 260 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 115 papers in Cancer Research, 110 papers in Oncology and 61 papers in Molecular Biology. Recurrent topics in Hans‐Peter Sinn's work include Breast Cancer Treatment Studies (85 papers), Breast Lesions and Carcinomas (43 papers) and HER2/EGFR in Cancer Research (37 papers). Hans‐Peter Sinn is often cited by papers focused on Breast Cancer Treatment Studies (85 papers), Breast Lesions and Carcinomas (43 papers) and HER2/EGFR in Cancer Research (37 papers). Hans‐Peter Sinn collaborates with scholars based in Germany, United States and Switzerland. Hans‐Peter Sinn's co-authors include Andreas Schneeweiß, Hans Kreipe, Sebastian Aulmann, H. Junkermann, Frederik Marmé, Gϋnter von Minckwitz, Christof Sohn, Peter Herrlich, M. Kaufmann and Helmut Ponta and has published in prestigious journals such as The Lancet, Angewandte Chemie International Edition and Nature Communications.

In The Last Decade

Hans‐Peter Sinn

240 papers receiving 8.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay

2013 836 citations Andreas Schneeweiß, Markus Wallwiener et al. profile →

Peers

Countries citing papers authored by Hans‐Peter Sinn

Since Specialization

Citations

This map shows the geographic impact of Hans‐Peter Sinn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans‐Peter Sinn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans‐Peter Sinn more than expected).

Fields of papers citing papers by Hans‐Peter Sinn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans‐Peter Sinn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans‐Peter Sinn. The network helps show where Hans‐Peter Sinn may publish in the future.

Co-authorship network of co-authors of Hans‐Peter Sinn

This figure shows the co-authorship network connecting the top 25 collaborators of Hans‐Peter Sinn. A scholar is included among the top collaborators of Hans‐Peter Sinn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans‐Peter Sinn. Hans‐Peter Sinn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Systematic profiling of primary invasive lobular breast carcinoma defines distinct candidates for PD-1/PD-L1 targeting immunotherapy 2024 ·European Journal of Cancer ·H. Böhm, (unknown), (unknown), Inka Zörnig, Dirk Jäger, Hans‐Peter Sinn, Carlo Fremd	0
2	Non-Response of Epstein–Barr Virus-Associated Breast Cancer after Primary Chemotherapy: Report of Two Cases 2023 ·Pathogens ·(unknown), Carlo Fremd, (unknown), Roland Penzel, (unknown), Hans‐Peter Sinn	0
3	B3-Läsionen der Mamma: Histologische, klinische und epidemiologische Aspekte 2023 ·PubMed ·Zsuzsanna Varga, Hans‐Peter Sinn, Annette Lebeau	3
4	Breast cancer characteristics and surgery among women with Li‐Fraumeni syndrome in Germany—A retrospective cohort study 2021 ·Cancer Medicine ·(unknown), Christine Fischer, Hans‐Peter Sinn, Nicola Dikow, Christian Sutter, Kerstin Rhiem, Sabine Grill, Friedrich W. Cremer, Huu Phuc Nguyen, Nina Ditsch, Karin Kast, Simone Hettmer, Christian P. Kratz, Sarah Schott	11
5	Clinicopathologic and molecular analysis of embryonal rhabdomyosarcoma of the genitourinary tract: evidence for a distinct DICER1-associated subgroup 2021 ·Modern Pathology ·F. Kommoss, Damian Stichel, Jaume Mora, Manel Esteller, David Jones, Stefan M. Pfister, (unknown), Marco Wachtel, Peter K. Bode, Hans‐Peter Sinn, Dietmar Schmidt, Thomas Mentzel, (unknown), (unknown), Felix Sahm, Andreas von Deimling, Christian Koelsche	35
6	Prädiktive Mutationsdiagnostik bei Mammakarzinomen 2021 ·Der Pathologe ·Hans Kreipe, Hans‐Peter Sinn	1
7	Chromothripsis in Human Breast Cancer 2020 ·Cancer Research ·Michiel Bolkestein, John Wong, Verena Thewes, Verena Körber, Mario Hlevnjak, (unknown), Markus Schulze, F. Kommoss, Hans‐Peter Sinn, Tobias Anzeneder, Steffen Hirsch, Frauke Devens, (unknown), Thomas Höfer, Andreas Schneeweiß, Peter Lichter, Marc Zapatka, Aurélie Ernst	17
8	Update der S3-Leitlinie Mammakarzinom: Was gibt es Neues für Pathologen? 2019 ·Der Pathologe ·Annette Lebeau, Carsten Denkert, Hans‐Peter Sinn, Marcus Schmidt, Achim Wöckel	1
9	Obesity as risk factor for subtypes of breast cancer: results from a prospective cohort study 2018 ·BMC Cancer ·(unknown), Mark Kriegsmann, Disorn Sookthai, Renée T. Fortner, Annika Steffen, Britta Walter, Theron Johnson, Jutta Kneisel, Verena Katzke, Manuela M. Bergmann, Hans‐Peter Sinn, Peter Schirmacher, Esther Herpel, Heiner Boeing, Rudolf Kaaks, Tilman Kühn	53
10	Spinale Mammakarzinommetastasen aus Sicht der Wirbelsäulenchirurgie: Prädiktoren auf Molekularebene zur Wahl der adäquaten Therapiestrategie 2018 ·Der Orthopäde ·D. Adler, Mark Kriegsmann, Hans‐Peter Sinn, Andreas Schneeweiß, Haidara Almansour, Burkhard Lehner, M. Akbar	0
11	Reprogramming of the ERRα and ERα Target Gene Landscape Triggers Tamoxifen Resistance in Breast Cancer 2015 ·Cancer Research ·Verena Thewes, Ronald Simon, (unknown), Magdalena Schlotter, Tobias Anzeneder, Reinhard Büttner, Vladimı́r Beneš, Guido Sauter, Barbara Burwinkel, Robert I. Nicholson, Hans‐Peter Sinn, Andreas Schneeweiß, Ulrich Deuschle, Marc Zapatka, Stefanie Heck, Peter Lichter	35
12	Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response? 2015 ·Annals of Surgical Oncology ·Benedikt Schaefgen, (unknown), Hans‐Peter Sinn, Michael Golatta, Anne Stieber, Geraldine Rauch, André Hennigs, (unknown), Christoph Domschke, Florian Schuetz, Christof Sohn, Andreas Schneeweiß, Joerg Heil	77
13	Breast Cancers with a BRCA1 -like DNA Copy Number Profile Recur Less Often Than Expected after High-Dose Alkylating Chemotherapy 2014 ·Clinical Cancer Research ·Philip C. Schouten, Frederik Marmé, Sebastian Aulmann, Hans‐Peter Sinn, Hendrik F. van Essen, Bauke Ylstra, Michael Hauptmann, Andreas Schneeweiß, Sabine C. Linn	30
14	Ulipristal Acetate for Symptomatic Uterine Fibroids and Myoma-Related Hypermenorrhea Joint Statement by the German Society for Gynecological Endocrinology and Reproductive Medicine (DGGEF) and the German Professional Association of Gynecologists (BVF) 2013 ·Journal für Kardiologie (Krause & Pachernegg GmbH) ·T. Rabe, (unknown), (unknown), Johannes Bitzer, Philippe Bouchard, U. Cirkel, Christian Egarter, K. König, (unknown), Matthias Matzko, (unknown), Thomas Römer, Thoralf Schollmeyer, Hans‐Peter Sinn, Thomas Strowitzki, (unknown), Markus Wallwiener, (unknown)	0
15	Variable expression of the Fragile X Mental Retardation 1 (FMR1) gene in patients with premature ovarian failure syndrome is not dependent on number of (CGG)n triplets in exon 1 2011 ·Human Reproduction ·(unknown), (unknown), J. Zimmer, Hans‐Peter Sinn, Cornelia von Hagens, T. Strowitzki, P. H. Vogt	32
16	A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer 2010 ·Annals of Oncology ·Andreas Schneeweiß, Frederik Marmé, A. Ruíz, Alexey Manikhas, Alberto Bottini, M. Wolf, Hans‐Peter Sinn, (unknown), Liam Kennedy, Thomas Bauknecht	17
17	Estrogen-Related Receptor α Expression and Function Is Associated with the Transcriptional Coregulator AIB1 in Breast Carcinoma 2009 ·Cancer Research ·Stefanie Heck, Joachim Rom, Verena Thewes, Natália Becker, Beatrix Blume, Hans‐Peter Sinn, Ulrich Deuschle, Christof Sohn, Andreas Schneeweiß, Peter Lichter	29
18	Intratumoral Cytokines and Tumor Cell Biology Determine Spontaneous Breast Cancer–Specific Immune Responses and Their Correlation to Prognosis 2009 ·Cancer Research ·Christoph Domschke, Florian Schuetz, Yingzi Ge, Tobias Seibel, Christine S. Falk, Benedikt Brors, Israël Vlodavsky, Nora Sommerfeldt, Hans‐Peter Sinn, (unknown), Andreas Schneeweiß, Alexander Scharf, Christof Sohn, Volker Schirrmacher, Gerhard Moldenhauer, Frank Momburg, Philipp Beckhove	47
19	Candidate Genes in Breast Cancer Revealed by Microarray-Based Comparative Genomic Hybridization of Archived Tissue 2005 ·Cancer Research ·Michelle Neßling, Karsten Richter, Carsten Schwäenen, Peter Roerig, Gunnar Wrobel, Swen Weßendorf, Björn Fritz, Martin Bentz, Hans‐Peter Sinn, Bernhard Radlwimmer, Peter Lichter	101
20	[May Perthes' disease be due to venous block? Experimental investigations on growing pigs]. 1977 ·PubMed ·(unknown), (unknown), Hans‐Peter Sinn	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact